See the DrugPatentWatch profile for ingrezza
What is Ingrezza for?
Ingrezza (valbenazine) is a prescription medicine used to treat certain movement disorders caused by abnormal dopamine signaling. It is specifically approved for tardive dyskinesia in adults and for chorea (involuntary, irregular movements) associated with Huntington’s disease [1].
What conditions does Ingrezza treat?
Ingrezza is prescribed for:
- Tardive dyskinesia (in adults), a condition that causes involuntary facial and body movements, often linked to long-term use of dopamine-blocking medications [1].
- Chorea due to Huntington’s disease (in adults) [1].
How does Ingrezza work for movement symptoms?
Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor. By affecting how neurotransmitters are packaged and released in nerve cells, it helps reduce abnormal involuntary movements in these disorders [1].
Who typically gets prescribed Ingrezza?
Doctors consider it when patients have:
- Persistent involuntary movements consistent with tardive dyskinesia, or
- Huntington’s disease with chorea symptoms that interfere with daily life [1].
What do people usually ask about when using Ingrezza?
Patients commonly ask about expected improvement, side effects, and whether other medications might interact. One notable interaction topic is how dosing or use may need adjustment when combined with certain drugs (for example, strong inhibitors of relevant metabolic pathways) [1].
Sources:
[1] https://www.drugs.com/ingrezza.html